This randomized, double-blind, placebo-controlled, two-period crossover study evaluated the efficacy of GSK2798745 versus placebo for reducing cough in patients with idiopathic or treatment-refractory chronic cough. As part of the study, cough was objectively measured using the Vitalograph VitaloJAK; recording was conducted 24 hours prior to dosing in each treatment period (baseline) and 24 hours following dosing on Day 7 in each treatment period.
- Author Ludbrook VJ et al.
- Publication ERJ Open Research
- Year 2021
- Device Type VitaloJAK
